Dorry Segev to Immunosuppressive Agents
This is a "connection" page, showing publications Dorry Segev has written about Immunosuppressive Agents.
Connection Strength
0.299
-
Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients. Transplantation. 2021 11 01; 105(11):e265-e266.
Score: 0.062
-
Early Changes in Kidney Transplant Immunosuppression Regimens During the COVID-19 Pandemic. Transplantation. 2021 01 01; 105(1):170-176.
Score: 0.059
-
Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data. Clin Transplant. 2020 12; 34(12):e14118.
Score: 0.058
-
Clinical Trials for Immunosuppression in Transplantation: The Case for Reform and Change in Direction. Transplantation. 2017 07; 101(7):1527-1534.
Score: 0.046
-
Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Taking Belatacept. Transplantation. 2021 09 01; 105(9):2119-2123.
Score: 0.015
-
Immunosuppression practices during the COVID-19 pandemic: A multinational survey study of transplant programs. Clin Transplant. 2021 08; 35(8):e14376.
Score: 0.015
-
Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. Transplantation. 2021 05 01; 105(5):e56-e57.
Score: 0.015
-
Early Development and Durability of SARS-CoV-2 Antibodies Among Solid Organ Transplant Recipients: A Pilot Study. Transplantation. 2021 05 01; 105(5):e52-e53.
Score: 0.015
-
Temporal Changes in the Impact of HLA Mismatching Among Pediatric Kidney Transplant Recipients. Transplantation. 2019 06; 103(6):1267-1271.
Score: 0.013